Please call your physician’s office before coming in for your appointment if you have symptoms of a cough, fever, or difficulty breathing; traveled to Europe or China or other areas impacted by the coronavirus (COVID-19) within the past 14 days; been in close contact with someone who has traveled outside the U.S. to one of the impacted countries; or may have been exposed to the coronavirus. Effective Monday May 18th all VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Timothy A. McCarthy, MD

VCS Physicians

Timothy A. McCarthy, MD Headshot

“We are at an exciting time in the care of patients with cancer. We continue to have newer, better treatments – advancing our knowledge, enabling us to target these therapies more to each individual. At VCS you can be assured that you will receive state-of-the-art cancer care that is the best plan for you and your family.”

Work and Credentials:

Primary Location

Fairfax Office


Medical Oncologist

Board Certification

Medical Oncology, Hematology and Internal Medicine


University of North Carolina Hospitals, Medical Oncology and Hematology


Rutgers Robert Wood Johnson Medical School

Medical School

Rutgers Robert Wood Johnson Medical School


Rutgers University

Dr. Timothy A. McCarthy graduated with high honors from Rutgers University where he received a Bachelor of Science in Materials Engineering.  He then went on to earn his medical degree and complete an Internal Medicine residency at Rutgers Robert Wood Johnson Medical School.  During his residency, Dr. McCarthy was honored with the Nilesh Tamakuwala, MD Memorial Award, a distinction presented to the individual who best demonstrated compassion in care and excellence in teaching.

Board-certified in Medical Oncology, Hematology and Internal Medicine, Dr. McCarthy completed his fellowship in Medical Oncology and Hematology at University of North Carolina Hospitals.  As an Oncology Fellow, Dr. McCarthy took a leadership role working with various departments with a specific interest in quality and process improvement projects.  Dr. McCarthy is a published author and has presented posters at various medical events, including the annual American Society of Clinical Oncology (ASCO) symposium.

Outside of medicine, Dr. McCarthy enjoys staying active and exploring the outdoors with his wife and 3 young children. He also enjoys listening to a diverse array of music and plays several different instruments.

Practice Blog

September 7, 2017

Timothy A. McCarthy, MD

Read More

Physician Publications

April 30, 2019

Fighting Brain Cancer at Virginia Cancer Specialists VCS:  Better Options, Better Outcomes -  Timothy A. McCarthy, MD

Read More
January 30, 2018

Northern Virginia 2018 Thoracic Oncology Symposium, CME Program - March 10th 2018

Read More
January 23, 2018

Boy Scout supports cancer patients with a very special Eagle Scout project

Read More

More Publications by Timothy A. McCarthy, MD

January 1, 2016

Importance of pharmacokinetic studies in the management of acquired factor X deficiency

Read More
July 14, 2014

Angiogenesis Inhibitors in Gastric Cancer

Read More

Clinical Trials (3)

Clinical Trial 18065

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Clinical Trial 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Clinical Trial D6070C00005

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab(MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Primary Location

Fairfax Office Office

Fairfax Office

Learn More


January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018